SNGX
Soligenix
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
News
- Soligenix reported interim results from the Phase 3 FLASH2 trial of HyBryte for cutaneous T-cell lymphomaApr 28, 2026
- HyBryte study results showed positive outcomes versus Valchlor in cutaneous T-cell lymphoma and were publishedApr 2, 2026
- Soligenix received EU orphan drug designation for SGX945 in Behçet's diseaseMar 26, 2026
- Soligenix announced SGX945 received Promising Innovative Medicine designation from the UK MHRAMar 10, 2026
- Soligenix received a positive opinion from the EMA on orphan drug designation for SGX945 in Behçet's diseaseFeb 26, 2026